BOSTON--(BUSINESS WIRE)--An analysis of immune markers measured in a sub-study of ViroStatics’ proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load. VS411 is a first-generation AV-HALT (antiviral-hyperactivation limiting therapeutic) designed to reduce both viral load and the state of chronic activation that exists in HIV-infected individuals. The analysis was presented today at the 18th Conference on Retroviruses and Opportunistic Infections.
